Nipocalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | FcRn |
| Clinical data | |
| Trade names | Imaavy |
| Other names | nipocalimab-aahu |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625078 |
| License data |
|
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6266H9722N1670O1992S46 |
| Molar mass | 141797.16 g·mol−1 |
Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis. It is a neonatal Fc receptor blocker. It is a high affinity, fully human, aglycosylated, effectorless immunoglobulin G (IgG) anti-FcRn monoclonal antibody.
Nipocalimab is a human IgG1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), thereby decreasing the levels of circulating IgG, including pathogenic IgG autoantibodies.
Nipocalimab was approved for medical use in the United States in April 2025, and in the European Union in November 2025.